D. Western Therapeutics Institute, Inc. (4576) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

RaQualia Pharma, Inc.

Wakamoto Pharmaceutical Co., Ltd.

Solasia Pharma KK

Nippon Chemiphar Co., Ltd.

Pharmarise Holdings Corp.

D. Western Therapeutics Institute, Inc.

Renascience, Inc.

BrightPath Biotherapeutics Co., Ltd.

SymBio Pharmaceuticals Ltd.

CanBas Co., Ltd.

Delta-Fly Pharma, Inc.

Why is D. Western Therapeutics Institute, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

The company has declared Negative results for the last 12 consecutive quarters

NET SALES(Q) At JPY 90.52 MM has Fallen at -13.74%
INTEREST(Q) Highest at JPY 2.74 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -18.10%, its profits have fallen by -4.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -18.10% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is D. Western Therapeutics Institute, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

D. Western Therapeutics Institute, Inc.

-18.1%

0.08

71.88%

Japan Nikkei 225

40.96%

1.35

28.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.08%

EBIT Growth (5y)

-261.93%

EBIT to Interest (avg)

-152.17

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.63

Sales to Capital Employed (avg)

0.24

Tax Ratio

0.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.43

EV to EBIT

-4.65

EV to EBITDA

-4.88

EV to Capital Employed

12.96

EV to Sales

10.36

PEG Ratio

Dividend Yield

ROCE (Latest)

-278.61%

ROE (Latest)

-105.85%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -76.95 %

OPERATING PROFIT(Q)

Highest at JPY -129.45 MM

PRE-TAX PROFIT(Q)

Highest at JPY -138.09 MM

NET PROFIT(Q)

Highest at JPY -138.49 MM

EPS(Q)

Highest at JPY -2.44

-21What is not working for the Company

NET SALES(Q)

At JPY 90.52 MM has Fallen at -13.74%

INTEREST(Q)

Highest at JPY 2.74 MM

Here's what is working for D. Western Therapeutics Institute, Inc.

Operating Profit

Highest at JPY -129.45 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JPY MM)

Pre-Tax Profit

Highest at JPY -138.09 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

Highest at JPY -138.49 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

EPS

Highest at JPY -2.44

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (JPY)

Debt-Equity Ratio

Lowest at -76.95 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for D. Western Therapeutics Institute, Inc.

Net Sales

At JPY 90.52 MM has Fallen at -13.74%

over average net sales of the previous four periods of JPY 104.94 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Interest

At JPY 2.74 MM has Grown at 30.83%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest

Highest at JPY 2.74 MM

in the last five periods and Increased by 30.83% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)